key: cord-0818453-405of4zr authors: Cavanna, Luigi; Citterio, Chiara; Biasini, Claudia; Madaro, Serena; Bacchetta, Nicoletta; Lis, Anna; Cremona, Gabriele; Muroni, Monica; Bernuzzi, Patrizia; Lo Cascio, Giuliana; Schiavo, Roberta; Mutti, Martina; Tassi, Maristella; Mariano, Maria; Trubini, Serena; Bandieramonte, Giulia; Maestri, Raffaella; Mordenti, Patrizia; Marazzi, Elisabetta; Vallisa, Daniele title: COVID-19 vaccines in adult cancer patients with solid tumors undergoing active treatment: seropositivity and safety. A prospective observational study in Italy date: 2021-09-02 journal: Eur J Cancer DOI: 10.1016/j.ejca.2021.08.035 sha: cd143d126def6e9d686c399aad752d6a99fda787 doc_id: 818453 cord_uid: 405of4zr INTRODUCTION: Cancer patients are presumed a frail group at high risk of contracting coronavirus disease (COVID-19), and vaccination represents a cornerstone in addressing the COVID-19 pandemic. However, data on COVID-19 vaccination in cancer patients are fragmentary and poor. METHODS: An observational study was conducted to evaluate the seropositivity rate and safety of a two-dose regimen of the BNT162b2 or mRNA-1273 vaccine in adult patients with solid cancer undergoing active anticancer treatment or whose treatment had been terminated within 6 months of the start of study. The control group was composed of healthy volunteers. Serum samples were evaluated for SARS-COV-2 antibodies prior vaccinations and 2-6 weeks after the administration of the second vaccine dose. Primary endpoint: seropositivity rate. Secondary endpoints: safety, factors influencing seroconversion, IgG titers of patients versus healthy volunteers, COVID-19 infection. RESULTS: Between 20 March 2021 and 12 June 2021, 293 consecutive cancer patients with solid tumors underwent a program of COVID-19 vaccinations: of these, 2 patients refused vaccination, 13 did not receive the second dose of the vaccine due to cancer progression and 21 had COVID-19 antibodies at baseline and were excluded. The 257 evaluable patients had a median age of 65 years (range 28-86), 66.15% with metastatic disease. Primary endpoint: seropositivity rate in patients was 75.88%, versus 100% in the control group. Secondary endpoints: no grade 3-4 side effects, no COVID-19 infections were reported. Patients median IgG titer was significantly lower than in the control group, male sex and active anticancer therapy influenced negatively seroconversion. BNT162b2 or mRNA-1273 vaccines were immunogenic in cancer patients, showing good safety profile. Coronavirus disease 2019 (COVID-19) is a highly infectious virus that has caused considerable discomfort and death worldwide. It has been reported that mortality from COVID-19 is higher in patients with cancer [1] [2] [3] . Most cancer patients are elderly and have other comorbidities, such as hypertension, diabetes, coronary disease, and chronic obstructive pulmonary disease, which are risk factors for severe disease and death [2, 3] . Cancer patients are at high risk of acquiring COVID-19 due to poor general condition and a systemic immunosuppressive state caused by cancer itself and/or anticancer treatment; in addition, cancer patients have frequent scheduled visits to hospital and clinics that can increase their risk of catching COVID-19 [4] . As previously reported, patients with cancer have a markedly elevated risk of intubation, Intensive Care Unit (ICU) admission, and death, whether these patients are receiving active anticancer treatment or are cancer survivors [5] . We previously reported cases involving the first 25 cancer patients with COVID-19 pneumonia in the Western world, and we found a mortality rate of 36.00% [2] . Additionally, cases involving 51 cancer patients with COVID-19 were reported by our group, and we found a COVID-19-related mortality rate of 23.53% [3] . Given the greater severity of COVID-19 in cancer patients and their higher risk of death, patients with cancer are considered a high-priority subgroup for vaccination against COVID-19, and while vaccines against COVID-19 have shown a high efficacy, immunocompromised patients were not included in controlled trials [6] . Limited data has been available on the efficacy, tolerability, and safety of COVID-19 vaccines in patients with cancer, because cancer patients were excluded from clinical trials of COVID-19 vaccines [7] . It must be emphasized that the major organizations of Western countries, such as the American Society of Clinical Oncology, the Association of Cancer Research, and the Association of American Cancer Institute in the United States and the European Society of Medical Oncology, the Society of Immunotherapy and Cancer, and the Italian Medical Oncology Association, in Europe recommended the vaccination of all cancer patients, including those receiving active anticancer therapy [8] [9] [10] [11] [12] [13] . Vaccines (BNT162b2 and mRNA-1273) were approved [14] and recommended by the United States Food and Drug Administration (FDA) and the European Medicines Agency to prevent COVID-19 disease. BNT162b2 and mRNA-1273 are lipid nanoparticle-encapsulated messenger RNA (mRNA)-based vaccines [14, 15] . In Phase III trials, these vaccines had 94.00% to 95.00% efficacy in preventing symptomatic SARS-CoV-2 infection independent of age [16, 17] . Cancer patients undergoing active treatment make frequent visits to hospitals or clinics, which can increase the risk of COVID-19 exposure, so their prioritization for vaccination is imperative [7] ; however, there is a paucity of data on the efficacy and safety of mRNA COVID-19 vaccines in cancer patients [18] [19] [20] [21] . In this study, we have reported preliminary findings evaluating the BNT162b2 (Pfizer-Biontech) and mRNA-1273 (Moderna) vaccines against COVID-19 in terms of their antibody-mediated response and tolerability in patients with cancer. This observational study was conducted at the Oncology-Hematology Department of Piacenza General Hospital (North Italy) to investigate the immunogenicity of COVID-19 vaccines in a prospective study, which was approved by the local Ethics Committee (Institutional Review Board approval number 317/2021/OSS/ASLPC). COVID-19 vaccination was proposed to all cancer patients attending the inpatient and outpatient clinic of the oncology-hematology department Hospital of Piacenza, by oncologists and trained nurses. All patients gave signed informed consent. This study also included a control group of J o u r n a l P r e -p r o o f healthy volunteers who were ≥ 18 years undergoing anti-COVID-19 vaccination during the same period. Patients were vaccinated through national and regional Italian programs and were vaccinated at the Oncology-Hematology Department of Piacenza General Hospital. All participants were given the two-dose regimen of the BNT162b2 mRNA vaccine (Pfizer-Biontech) or the mRNA-1273 vaccine (Moderna) via intramuscular injection in the deltoid muscle according to the manufacturer's technical instructions. The vaccine was administered to patients undergoing cytotoxic chemotherapy 1-2 weeks before or 1-2 weeks after their drug dose. The vaccine was administered to patients treated with biological therapy (like monoclonal antibodies and tyrosine kinase inhibitor), hormone therapy, or immune checkpoint inhibitors when available as recommended [7] . For all cancer patients undergoing anticancer treatment, a complete blood cell count was conducted before vaccination, and vaccination was delayed until absolute neutrophil count recovery. Eligibility criteria for vaccination were as follows: cancer patients with a solid tumor, age ≥ 18 years, on active anticancer treatment or whose treatment had been terminated up to 6 months before the study period, with no known history of SARS-COV-2 infection or at least 3 months after testing positive for COVID-19. The blood serum of cancer patients was tested to evaluate serum IgG antibody levels against SARS-COV-2 up to two days before vaccination (T0) and 2-6 weeks after the administration of the second vaccine dose. Exclusion criteria were as follows: active COVID-19 infection, patients with a baseline IgG value of ≥ 15 AU/ml were vaccinated but were excluded from this study. The primary endpoint was the proportion of patients who acquired anti-SARS-COV-2 antibodies after two doses of vaccination. The secondary endpoints were as follows:  safety;  the role of age, gender, anticancer treatment, type and stage of cancer on vaccine seropositivity;  the diagnosis of symptomatic or asymptomatic post-vaccine COVID-19 infection.  Median IgG titer of patients versus healthy volunteers. All vaccinated patients were followed and/or treated for their oncologic disease, and the COVID-19 swab test was performed in our department, as previously reported [22, 23] , for each patient attending the Oncology Clinic, and this was repeated in asymptomatic patients every month. All patients were informed to call specialized nurses of the Oncology Department to report any adverse events related to the vaccination and they completed a questionnaire between 1, 2, and 4 weeks after the first and the second vaccination dose. Serum samples were analyzed and evaluated for SARS-CoV-2 antibody with LIAISON SARS-CoV-2 S1-S2 IgG [24, 25] , performed according the manufacturer's technical instructions, which use an automated platform, LIAISON XL, for the detection of IgG against subunits S1 and S2 of the SARS-CoV-2 spike protein Results were calculated referring to a calibration curve and expressed in binding antibody units (AU)/ml, a value ≥15 AU/ml was considered positive according to the manufacturer's instructions. Patients were registered with a unique recognition code in a Microsoft Excel file (Microsoft Office version 2010). Quantitative variables were described by median and IQR and qualitative variables were described by absolute and percentage frequencies. Normality was checked for all continuous variables. Comparisons of covariates were conducted using Pearson's X 2 test or Fisher's exact test for categorical variables and a ttest or Mann Whitney test for continuous variables. A univariable analysis was conducted using logistic regression to examine the association of each predictor variable with the response status of the patient. Next, significant variables (p < 0.05) were considered for inclusion in a multivariable regression model. For each risk factor, odds ratio (OR) with associated confidence intervals have been presented. All analyses were performed using RStudio version 3.6.0 statistical software with two-sided significance tests and a 5 % significance level. In total, 293 consecutive oncology patients attending the Oncology/Hematology Department of the Piacenza General Hospital between 20 March 2021 and 12 June 2021 were included in the study. Of these, 2 patients refused vaccination, 13 did not receive the second dose of the vaccine due to cancer progression and 21 had a baseline IgG value of ≥ 15 AU/ml and were excluded from the evaluation of their serologic response to vaccination. Thus, the final analysis included 257 consecutive evaluable patients that received two doses of the planned vaccines. Age was reported both as a continuous variable and for the range < and ≥ 65 years. The median age was 65 [IQR 57-72] years, 56.03% participants were female. Most patients (66.15%) were metastatic (Table 1) , and the most common cancers were breast (27.24%) and gastrointestinal (26.07%; Table 2 ). Others included bladder, prostate, brain, melanoma, sarcomas, and rare cancers. Overall, 219 patients (85.21%) were on active anticancer treatment (Table 3) , and the most common anticancer treatment was chemotherapy alone (46.30%). Primary endpoint: after the second dose, 195/257 patients (75.88%) had an IgG value of ≥ 15 AU/ml, and 62/257 patients (24.12%) did not show a serologic response, while seropositivity in the control group was 100%. Secondary endpoints: no grade 3 or 4 side effects were recorded. Overall, 31.52% and 33.46% of patients reported mild local reactions like pain and/or erythema at the site of vaccination after the first and second doses of the vaccine, respectively. The most frequently reported systemic reactions after the first dose of vaccine included weakness (7.00%), headache (8.17%), and muscle pain (2.72%). Systemic side effects more frequently reported after the second dose of vaccine were weakness (8.90%) and fever (5.83%). The results from the multivariable logistic regression (Table 4) showed that male sex and active treatment (chemotherapy, immunotherapy, biological therapy alone, and chemotherapy plus biological therapy) were risk factors for negative seroconversion. The year range was removed from the multivariable model due to collinearity with the variable age at the time of vaccination. Forest plot of ORs (95%CI) have been reported in Figure 1 . Seroconversion according to sex has been reported in Figure 2 , and seroconversion according to treatment has been reported in Figure 3 . At short-term follow-up, no patients showed symptomatic or asymptomatic post-vaccine COVID-19 infection, regardless of seropositivity status. The median IgG titer in patients was statistically significantly lower than that in the control group (118 [IQR 16.9-401] AU/mL versus 380.5 [IQR 234-401] AU/mL, p < 0.001; Figure 4 ). J o u r n a l P r e -p r o o f People with cancer are at an increased risk of experiencing unfavorable outcomes resulting from COVID-19 infection, and recently published position papers, editorials, commentary, and reviews have supported the notion that patients with cancer must receive COVID-19 vaccination when possible [26, 27] . However, available clinical data on COVID-19 vaccination in cancer patients are fragmentary and poor [18] [19] [20] [21] . To our knowledge, this paper is one of the larger report of a prospective, single-center cohort study of anti-COVID-19 vaccination among patients with cancer in Europe. Many international guidelines do not recommend a specific timing of vaccination for patients in active treatment [7] ; however we chose to control neutrophil count, although this is not universally considered useful for vaccination, to guarantee greater safety to the patients. This cohort study showed that 195/257 (75.88%) cancer patients were seropositive for SARS-COV-2 antibody IgG at 15 to 42 days after the second dose of BNT162b2 or mRNA-1273 vaccination versus 100% of the control group. It is now well known that oncology patients have an increased risk of complications and mortality from COVID-19 [2, 3, 5, 28] , so they are considered a high priority subgroup of the population with regards to COVID-19 vaccination. We are aware that the correlation between antibody response to anti-COVID-19 vaccines and protection against SARS-COV-2 infection has not been well established in cancer patients. However, in our cohort of vaccinated cancer patients, despite the limitation of short-term follow-up, there was no symptomatic or symptomatic COVID-19 disease. As recently reported by our group, RT-PCR swabs taken from asymptomatic cancer patients attending the Outpatient Oncology Clinic, during the pre-vaccine era, were positive in 10/260 patients (3.85%) within a similar (two-months) period of observation [22] . Also in the group of patients with negative antibodies after vaccination (24.12%), no positive swab tests were recorded, which suggested a role of T-cell mediated immunity in patients with a poor humoral response. While the Centers for Disease Control and Prevention recommends against antibody testing for immunity assessment in response to mRNA COVID-19 vaccination [29] , and cellular immunity plays an important role in protecting against COVID-19, recent published data have shown that seropositivity is associated with protection from infection [30, 31] . A protective immune response to vaccines or viral infections is based on both humoral and cellular immune systems, and a good level of antibody response, as previously reported [32] , can also indirectly represent T lymphocyte activity (T helper CD4+), which activates and stimulates B lymphocytes to produce antibodies against the antigen. In addition, the response of T helper lymphocytes CD4+ to the viral spike protein is correlated with the degree of anti SARS-COV-2 IgG and IgA titers [33] . In our study cohort, most patients (75.88%) with cancer demonstrated seropositivity for SARS-COV-2 IgG antibodies, although this immunologic response was, as expected, inferior compared with seropositivity in the healthy control group (100%). The American Society of Infectious Disease recommends the vaccination of cancer patients at the time of lowest immunosuppression [34] ; according to this recommendation, our patients were vaccinated 1-2 weeks prior to the initiation of chemotherapy or 1-2 weeks before or after their chemotherapy drug dose, when white blood cells had recovered from chemotherapy. This optimized the potential for an immune response to the vaccine. Data on anti-COVID-19 vaccination in cancer patients are limited [18] [19] [20] [21] . Revon-Riviere et al. [19] reported a retrospective analysis of the safety and efficacy of BNT162b2 mRNA COVID-19 vaccines in adolescents and young adult patients with solid tumors with a median age of 17 years. Of the 10 patients tested, nine had positive serology one month after the second injection, and vaccines had a good safety profile. Iacono et al. [20] evaluated the seroprevalence of SARS-COV-2 IgG in 36 older cancer patients (age ≥ 80 years) after administering the second dose of the BNT162b2 vaccine and showed that older cancer patients can have a serologic response to this anti-COVID-19 vaccine. Thakkar et al. [21] reported a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received the full dose of an FDA-approved COVID-19 vaccine. To our knowledge, only two single-center prospective studies of mRNA vaccination for SARS-COV-2 among patients with cancer have been reported recently [18, 35] . In the first study [18] , researchers analyzed 102 cancer patients with a median age of 66 years (57% men) and showed that seropositivity for SARS-COV-2 anti-spike IgG antibodies after the second vaccine dose was 90%. This was higher than in our study; however, in the previous study, pre-vaccination antibody titers were not evaluated. In the second study [35] , 129 cancer patients, of which 70.5% metastatic, were vaccinated with BNT162b2 and monitored for antibody response and safety. Seropositivity rate among cancer patients and control was 32.4% vs 59.8% (p<0.0001) after second dose respectively. The seropositivity rate of this study is lower when compared with the results of our study. In our study, before vaccination, 21 (7.16%) patients were found to have antibodies and were excluded from our analysis. Our study was limited due to being performed at a single center; additionally, we did not analyze cellular immunity, and follow-up was short-term. We are evaluating booster vaccine doses in patients without seropositivity after two vaccine doses. As reported recently, [36] [37] [38] [39] [40] there is an unanimous agreement, that on the basis of the available evidence, for cancer patients, as for the population at large, the benefit of the vaccination outweigh the risks. Given the greater severity and higher risk of death from COVID-19 in cancer patients, vaccinating these patients should have a high priority, and we, as healthcare workers, need to make every possible effort to improve vaccination adherence by this group [40]. We conducted a prospective study of 257 consecutive evaluable patients, of which 219 (85.21%) were on active treatment. Following two doses of the BNT162b2 or mRNA-1273 vaccine, the antibody response rate in these patients was 75.88% versus 100% in the healthy control group. Interestingly only 2 on 293 patients (0.68%) refused vaccination, this high adherence to vaccine is likely due to finalized interviews with the patients. The vaccination was well tolerated without Grade 3 or 4 adverse events. To our knowledge, this is the largest study of cancer patients undergoing vaccination for SARS-COV-2 to date. Vaccination of cancer patients should be a priority, and patients in this study did not show signs of COVID-19 infection during vaccine follow-up. However, patients with cancer who have been vaccinated should continue to be prudent by wearing masks and engaging in social distancing and hand hygiene practices. Patients in this study are being followed to evaluate the duration of immunological response and eventual COVID-19 infection. Table 4 . Univariable and multivariable analysis of factors potentially associated with serologic response. Are all patients with cancer at heightened risk for severe Coronavirus Disease 2019 (COVID-19)? Coronavirus Disease-2019 in cancer patients. A report of the first 25 cancer patients in a Western country (Italy) Cancer patients with COVID-19: a retrospective study of 51 patients in the district of Piacenza Oncology care and education during the Coronavirus (COVID-19) pandemic Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Immune responses to COVID-19 mRNA vaccines in patients with solid tumors on active, immunosuppressive cancer therapy. medRxiv COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited Cancer groups urge CDC to prioritize cancer patients for COVID-19 vaccination SITC statement on SARS-CoV-2 vaccination and cancer immunotherapy. SIT Cancer National Comprehensive Cancer Network. Preliminary recommendations of the NCCN COVID-19 Vaccination Advisory Committee* Version 1.0 1/22/2021 The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate Documento AIOM CIPOMO COMU Vaccinazione COVID-19 per i pazienti oncologici ver 1 Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates An mRNA vaccine against SARS-CoV-2-preliminary report Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience Serological response to COVID-19 vaccination in patients with cancer older than 80 years Seroconversion rates following COVID-19 vaccination among patients with cancer Prevalence of COVID-19 Infection in Asymptomatic Cancer Patients in a District With High Prevalence of SARS-CoV-2 in Italy Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for Clinical and analytical performance of an automated serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively DiaSorin's LIAISON® SARS-CoV-2 Diagnostic Solutions Emerging issues related to COVID-19 vaccination in patients with cancer Vaccination of cancer patients against COVID-19: towards the end of a dilemma Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. Cancer Interim clinical considerations for use of COVID-19 vaccines Association of SARS-CoV-2 seropositive antibody test with risk of future infection Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host Efficacy and Safety of BNT162b2 Vaccination in Solid Cancer Patients Receiving Anti-Cancer Therapy -a Single Center Prospective Study Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.